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Abstract 
Background: Management of micrometastasis in the sentinel node is a controversial topic. 
Most of the guidelines don’t recommend further axillary treatment if micrometastasis are the 
only finding in the sentinel node. However, some evidence suggests that micrometastasis 
have significant effect on long term outcomes and therefore indicate systemic treatment. 
Method: Retrospective cohort study reviewing the management of patients with 
micrometastasis in the sentinel nodes. Two groups were compared, those who had further 
axillary clearance and those who had not. The primary endpoints were loco-regional 
recurrence and lymphoedema rate. The secondary endpoints were distant metastasis rate, OS 
and DFS. 
Results: 95 patients were found to have micrometastasis or ITC in the axillary SNB over a 
period of 10 years. Of those, 38 patients had axillary clearance after SNB, while 57 did not. 
Lymphedema rate was 18.4% in the axillary clearance group versus 0% in the no axillary 
clearance group (p < 0.001). The LRR event was rare therefore not compared. Distant 
metastasis rate was 7.01% in the SNB group versus 2.6% in the axillary clearance group. 
There were no mortalities in the axillary clearance group. This compares to 7.01% among the 
patients who didn’t have axillary clearance. All the patients who died had developed distant 
metastasis as a cause of death. There was a difference in OS between the two groups in favor 
of the axillary clearance group (p = 0.004). 
Discussion: Although not an indication for axillary clearance recent guidelines, 
micrometastasis and ITC found in the SNB are a sign of a biologically different disease. This 
important information should be taken in consideration when planning the adjuvant treatment 
in those patients among other factors considered.  
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 Introduction 
 
The further management of micrometastatic disease in the era of axillary sentinel node biopsy 
(SNB) has been evolving. Gradually, guidelines are shifting away from clearing the axilla if 
micrometastasis are found during sentinel node biopsy [1] [2] [3]. 
 The Association of Breast Surgery of England (ABS) consensus statement in 2014 on the 
management of the axilla reflected this [4]. The recent IBCSG 23-01 trial showed no 
difference in outcome in terms of disease free survival (DFS) or overall survival (OS) when 
axillary treatment was omitted for micrometastasis in SNB [5]. However, the earlier 
MIRROR study showed that patients with micrometastasis and isolated tumour cells (ITC) 
who didn’t receive systemic treatment had a higher event rate than those who did [6]. This 
suggests that micrometastases are a sign of a systemic disease, which needs to be considered 
when planning treatment for those patients. 
This is retrospective cohort study of breast cancer patients with sentinel node 
micrometastases. The aim of the study was to detect any difference in outcomes in patients 
with micrometastases in the sentinel node with and without axillary clearance. We compared 
two groups of patients from this cohort, those who had a subsequent axillary clearance and 
those who did not. The primary endpoints for comparison were loco-regional recurrence 
(LRR) and lymphedema. The secondary endpoints were distant metastasis rate, overall 
survival (OS) and disease-free survival (DFS). 
Micrometastasis are defined as metastatic disease in the axilla which is smaller than 2.0 mm 
but larger than 0.2 mm. Isolated Tumour Cells (ITC) are defined as metastatic disease smaller 
than or equal to 0.2 mm according to the American Joint Committee on Cancer (AJCC) 
staging manual [7]. 
Lymphoedema was defined as clinically evident swelling of the arm on the treated side, with 
referral to the lymphedema service. Loco-regional recurrence is defined as any tumour 
developing in the ipsilateral breast and/or the axilla after the primary treatment. Distant 
metastasis are define as any tumour metastasis developing in distal organs after completion of 
primary treatment.  
 
Patients and Methods 
 
This study was conducted at the Royal Devon and Exeter Hospital, treating more than 600 
new breast cancer patients per year.  We looked at all breast cancer patients who were 
diagnosed with micrometastasis in the axilla over a 10 years’ period (2006 to 2015). This 
cohort of patients was divided into 2 groups based on their subsequent management 
following the detection of SNB micrometastases: those who had a completion axillary 
clearance, and those who did not. Pathological characteristics of the primary tumour were 
recorded and accounted for in the statistical analysis. This included the histological subtype 
of the tumour (ductal, lobular and others); size and grade of the tumour; ER/PR and HER2 
receptor status. 
All patients had their treatment plan including adjuvant treatment considered and documented 
at the multidisciplinary team (MDT) meeting.  
Clinical follow-up was by physical examination 6 monthly for 2 years and annually thereafter 
up to 5 years with annual mammography for 5 years.  
The outcomes for the two groups were compared. The primary endpoints were LRR and 
lymphoedema rate and the secondary endpoints were distant metastasis rate, OS and DFS. 
Patients were excluded from the study if they had received neoadjuvant chemotherapy 
treatment, since this may have altered the tumour biology and confound the results. 
Radiotherapy schedules and boost fields were documented and considered in the multivariate 
analysis.  
Data were analyzed using IBM SPSS advanced statistics version 22 (SPSS Inc., Chicago, IL). 
Numerical data were expressed as mean and standard deviation or median and range as 
appropriate. Qualitative data were expressed as frequency and percentage. Chi-square test or 
Fisher’s exact test were used to examine the relation between qualitative variables. For non-
normally distributed data, comparison between two groups was done using Mann-Whitney 
test (non-parametric t-test). Survival analysis was done using Kaplan-Meier method and 
comparison between two survival curves was done using log-rank test. All tests were two-
tailed. A p-value < 0.05 was considered significant. 
 
Results 
 
From 2006 to 2015, 95 patients were found to have micrometastasis or ITC in the axillary 
SNB. Of those, 38 patients had axillary clearance following SNB, while 57 did not. 
The tumor characteristics, size of micrometastasis and adjuvant treatment within the two 
groups are summarized in Table 1. The median follow-up duration was 34.2 months. Two 
patients left from Exeter after a short follow-up period and were therefore not included in the 
survival analysis. Six patients had received neoadjuvant chemotherapy and were excluded. 
54 patients (56.84%) were treated with wide local excision, while 41 (43.15%) had a 
mastectomy. 
There was a statistically significant difference in the rates of lymphoedema between the two 
groups. Lymphedema rate was 18.4% (7 patients) in the axillary clearance group versus 0% 
(0 patients) in the no axillary clearance group (Chi Square test, p < 0.001). 
There was no detectable difference in the loco-regional recurrence rate between the two 
groups. The LRR event was rare. Only one patient in the no axillary clearance patients group 
developed local recurrence during the period of the study. This axillary recurrence was 
detected after 5 years from the initial treatment. 
Four patients of the 57 who had SNB only (7.01%) developed distant metastasis during the 
follow-up period of the study. While only one patient of the 38 in axillary clearance group 
(2.6%) developed distant metastasis. 
There were no deaths during the period of follow-up within the axillary clearance group. This 
compared to 7.01% among SNB only cohort. The distant metastasis in this cohort developed 
at 1, 3, 4 and 5 years following initial treatment. All the patients who died had already 
developed distant metastasis. Three of the four patients died within the same year of the 
diagnosis of distant metastasis, while one patient died 3 years later. 
The cumulative 5 years OS of all patients with micrometastatic disease was 84.7%. 
There was a statistically significant difference when DFS survival analysis was done using 
Kaplan-Meir curve between the two groups.  The difference was 40% in favor of the axillary 
clearance group (Mantle-Cox test, p = 0.004). This is shown in Figure 1. 
There was similar difference in DFS between the two groups, although this was not 
statistically significant (p = 0.1). Figure 2. 
On multivariate analysis of OS between the two groups, axillary clearance remained the only 
significant factor accounting for the statistical difference. Analysis included size of 
micrometastasis (p = 0.664), size of the tumor (p = 0.981), grade of the tumor (p = 0.2), 
adjuvant radiotherapy (p= 0.418), adjuvant chemotherapy (p= 0.747) and adjuvant Herceptin 
(p= 0.567). However, endocrine treatment showed a difference but this did not quite reach 
significance, with a p value of 0.054. Table 1. 
Of the 57 the patients within the SNB only group, 10 patients had the axilla included in the 
field of radiotherapy. All 10 were treated during the last 5 years. None of these patients 
developed lympoedema, in contrast with those who had axillary clearance (p = 0.013).  
Among the axillary clearance group, 11 patients had axillary clearance upfront without SNB 
for various reasons. The only finding in the axillary nodes however was micrometastasis or 
ITC. Those patients were included within the axillary clearance following SNB group as they 
have same natural history. 
In the 28 patients who had axillary clearance following SNB, three patients had further 
positive axillary lymph nodes (10.7%). None of which had more than two further nodes 
containing metastases. All the further positive nodes contained micrometastatic disease. 
 
Discussion 
 
This study addresses the question of whether axillary clearance can be safely omitted when 
micrometastasis or ITC are found in the sentinel node. This remains a controversial issue as 
data from different studies are being published [8] [9]. 
In our study, axillary clearance did not add much staging information when it was performed 
following micrometastasis in SNB. Only 10% of patients had further axillary disease and 
none had more than 2 further positive lymph nodes. The rate of lymphedema was 
significantly higher in patients who had axillary clearance, this is in concordance of the 
established evidence available [10]. 
There was a 7% difference in mortality between the two groups. Of those patients, 50% have 
not received any adjuvant systemic treatment. It is fair to say that micrometastasis detected in 
the SNB indicate a systemic disease not only an axillary localized disease. In this aspect, our 
study results correlate with the MIRROR trial results where the micrometastasis were found 
to be a  sign of a different systemic disease that needs to be considered in the algorithm of 
adjuvant treatment planning [11].  
There was a statistically significant difference in the cumulative OS and DFS between the 
two groups of patients in this study which was in favor of axillary clearance. However, there 
was also statistically significant effect on OS noticed with endocrine treatment in ER positive 
patients and also with patients where radiotherapy field was extended to tangentially include 
the axilla. This result correlates with the ACOSG Z-001 study results where all patients 
reportedly received some form of radiotherapy to the axilla by modifying the field [12]. 
Lymphedema was higher in patients who had axillary clearance compared to those who had 
axillary radiotherapy. This result is concordant with the recent AMAROS trial published data 
[13]. 
We recognize many limitations to our study. Primarily, this is a retrospective cohort study 
over 10 year’s duration. During those 10 years, the treatment of the axilla has markedly 
changed. This is reflected in our study by the fact that most of the patients who didn’t receive 
further axillary clearance for micrometastasis were the more recent patients in the study. The 
number of patients in the study could be a limitation too, but is comparable to other 
retrospective studies who tried to address the topic [14] [15] [16]. The median follow-up 
period of the study is also short. The molecular classification of the tumour was not included 
as a prognostic factor in this study. 
However, the main limitation of our study is the small number of events in both groups. This 
particularly affects the survival analysis and makes accounting to different factors in the 
analysis not statistically significant. Therefore, data and conclusions should be taken with 
caution. 
The data regarding the axilla inclusion in radiotherapy field should be taken with caution. 
The number of patients with those criteria is very small despite the statistical significance of 
the results. 
Although not an indication for axillary clearance in most of the recent guidelines, 
micrometastasis and ITC found in the SNB seem to affect the survival of the patients. 
This important information should be taken in consideration when planning the adjuvant 
treatment in those patients among other factors considered.  
On the basis of current evidence axillary clearance could probably be safely omitted after 
SNB when micrometastasis or ITC are found given the higher rate of lymphedema and the 
little staging information it further adds [17]. But, on making this decision, the field of 
radiotherapy and the adjuvant systemic treatment need to be considered. This is concordant 
with the ABS consensus statement which takes in consideration in the algorithm of further 
axillary treatment many factors. Namely the type of surgical treatment (mastectomy versus 
breast conserving) and therefore the radiotherapy and its field and also the ER receptor status 
and therefore endocrine treatment [4].   
Our discussion is that although micrometastatic disease in the axilla doesn’t dictate further 
axillary surgery, it is an indication of a biologically different systemic disease. This needs to 
be taken in consideration when planning adjuvant systemic treatment in those patients as it 
clearly affects their survival. 
Currently, there are no enough data to support the use of more aggressive systemic therapies 
when ITC and micrometastases are found in the sentinel node. The data from different studies 
are controversial. 
However, the question of the impact micrometastasis have on the OS of the patients remains 
to be addressed. Further prospective study of long-term follow-up of patients is required, with 
design of high quality randomized studies desirable.   
  
Table 1. Characteristics of the two groups of patients 
 
 
  
 SNB  ANC P value 
Total number 
 
Number of 
Micrometastases 
               ITC 
               1  
               2 
 
Median Size of 
Micrometastases 
 
Median Number of 
Nodes at the SNB 
 
57 (100%) 
 
 
 
3 (5.2%) 
48 (83.2%) 
6 (10.5%) 
 
0.73 mm 
 
 
2.9 
38 (100%) 
 
 
 
4 (10.5%) 
31 (81.5%) 
3 (7.8%) 
 
0.63 mm 
 
 
1.74 
 
Tumour Type  
                IDC 
                ILC 
               Other 
 
 
51 (89.4%) 
5 (8.7%) 
1 (1.7%) 
 
30 (78.9%) 
6 (15.7%) 
2 (5.2%) 
 
0.158 
Tumour Size 
               <20 mm 
               >20 mm 
 
 
34 (59.6%) 
23 (40.3%) 
 
20 (52.6%) 
18 (47.3%) 
0.500 
Tumour Grade 
               1 
               2 
               3 
               Not available 
 
 
10 (17.5%) 
33 (57.8%) 
12 (21%) 
2 (3.5%) 
 
3 (7.8%) 
25 (65.7%) 
10 (26.3%) 
 
0.439 
Surgery 
              Mastectomy 
              WLE 
 
19 (33.3%) 
38 (66.6%) 
 
22 (57.8%) 
16 (42.1%) 
 
 
Adjuvant Treatment 
      Chemotherapy 
      Herceptin 
      Radiotherapy 
      Endocrine Treatment 
 
 
16 (28%) 
4 (7%) 
49 (85.9%) 
48 (84.2%) 
 
17 (44.7%) 
4 (10.5%) 
30 (78.9%) 
35 (92.1%) 
 
0.095 
0.727 
0.371 
0.256 
Loco-Regional 
Recurrence 
 
1 (1.7%) 0 (0%) 0.419 
Distant Metastasis 
 
4 (7%) 1 (2.6%) 0.346 
Lymphedema 
 
0 (0%) 7 (18.4%) <0.001 
Mortality 4 (7%) 0 (0%) 0.048 
 Figure 1. Overall Survival between the two groups 
 
 
Figure 2.  Disease Free Survival between the two groups 
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